Pfizer Inc. $PFE Holdings Raised by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 13.4% in the fourth quarter, Holdings Channel reports. The firm owned 445,948 shares of the biopharmaceutical company’s stock after buying an additional 52,827 shares during the period. Pfizer accounts for 1.2% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 28th largest holding. Marble Harbor Investment Counsel LLC’s holdings in Pfizer were worth $11,104,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Horizon Financial Services LLC raised its stake in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Pfizer during the 4th quarter valued at $28,000. HFM Investment Advisors LLC raised its holdings in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the 3rd quarter valued at $29,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Pfizer during the 2nd quarter valued at $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. Morgan Stanley raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Citigroup raised their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. HSBC raised their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Finally, Wolfe Research reissued an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.84.

Pfizer Stock Performance

Shares of PFE opened at $25.66 on Wednesday. The company has a market capitalization of $146.27 billion, a PE ratio of 19.59 and a beta of 0.35. Pfizer Inc. has a one year low of $22.81 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company’s fifty day moving average price is $26.93 and its 200 day moving average price is $26.21.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is presently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a new Phase 3 endometrial cancer trial, signaling continued investment in its oncology pipeline and a potential long-term growth driver. Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Several recent opinion pieces argued that Pfizer still looks undervalued, which may be supporting bargain-hunting interest in the stock. Why Pfizer Stock Still Looks Deeply Undervalued In 2026
• Positive Sentiment: Technical commentary noted Pfizer’s RSI moved above 50, which traders often read as a sign of improving momentum. Tata Motors PV among 6 stocks showing bullish RSI upswing
• Neutral Sentiment: Analyst coverage remained unchanged at “Hold,” suggesting the market still sees Pfizer as fairly valued despite recent catalysts. Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: Pfizer and other big drugmakers came under pressure after reports that the TrumpRx drug-pricing initiative may be set for “dramatic expansion,” reviving policy overhang concerns for the sector. PFE, NVO, LLY: Pharma Stocks Drop on News TrumpRx Set for ‘Dramatic Expansion’

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.